Journal
DRUGS OF TODAY
Volume 55, Issue 10, Pages 627-639Publisher
PROUS SCIENCE, SAU-THOMSON REUTERS
DOI: 10.1358/dot.2019.55.10.3045038
Keywords
Viltolarsen; NS-065/NCNP-01; Duchenne muscular dystrophy; Antisense therapy; Oligonucleotides; Phosphorodiamidate morpholino oligomers; Gene therapy
Categories
Funding
- Muscular Dystrophy Canada
- Friends of Garrett Cumming Research Fund
- HM Toupin Neurological Science Research Fund
- Canadian Institutes of Health Research (CIHR)
- Alberta Innovates: Health Solutions (AIHS)
- Jesse's Journey
- Women and Children's Health Research Institute (WCHRI)
Ask authors/readers for more resources
Duchenne muscular dystrophy is the most common lethal X-linked genetic disorder, characterized by progressive muscle loss, with cardiac and respiratory complications. It is caused by a lack of dystrophin protein due to mutations in the DMD gene, which can disrupt the reading frame of the dystrophin primary transcript. Antisense oligonu-cleotides such as phosphorodiamidate morpholino oligomers (PMOs) can induce exon skipping during pre-mRNA splicing and restore the reading frame of the DMD primary transcript. The resulting dystrophin protein is internally deleted but partially functional. Viltolarsen, also known as NS-065/NCNP-01, is a PMO developed through comprehensive sequence optimization and is designed to skip exon 53 on the DMD primary transcript. Exclusion of exon 53 from the DMD primary transcript can treat 8-10% of DMD patients worldwide. This review paper summarizes the mechanism of action, pharmacokinetics and safety of viltolarsen from preclinical and clinical trials.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available